Related
Ipsen Enters Collaboration with Skyhawk for RNA-Targeted Therapies for Neurological Diseases
Rare Daily Staff Ipsen said it entered into an exclusive, worldwide collaboration to discover and develop small […]
Read moreLexeo Enters Data Collaboration with Cornell to Accelerate Development of Gene Therapy for FA Cardiomyopathy
Rare Daily Staff Lexeo Therapeutics entered an in-license agreement with Cornell University to expedite development of the […]
Read moreFDA Grants Breakthrough Therapy Designation for Kura’s Treatment for NPM1-Mutant AML
Rare Daily Staff The U.S. Food and Drug Administration granted Breakthrough Therapy designation for Kura Oncology’s ziftomenib […]
Read moreSynOx Raises $75 Million to Advance Development of Potential Treatment for TGCT
Rare Daily Staff Irish biotech SynOx Therapeutics raised $75 million in a series B financing to advance […]
Read moreKorro Bio Raises $70 Million to Advance RNA Edited Therapies
Rare Daily Staff Korro Bio, which is developing a new class of genetic medicines based on editing […]
Read moreRNA-Targeted Therapy Shows Promise for a Rare Childhood Dementia
Rare Daily Staff A study in mice suggests a new RNA-targeted therapy can halt the progression of […]
Read moreExpanding Access to Genome Sequencing in Rural Populations
Rare Daily Staff Patients in rural area often face challenges accesses cutting-edge medical technologies, such as state-of-the-art […]
Read moreA Small Molecule Therapy to Regenerate Muscle in People with DMD
Duchenne muscular dystrophy is an inherited disease caused by genetic mutations that no longer allow the dystrophin […]
Read moreArgenx Highlights gMG Drug Data in CIDP
Rare Daily Staff Argenx said that positive data from its phase 3 ADHERE trial evaluating Vyvgart Hytrulo […]
Read more